Related Experiment Video
Updated: Jan 15, 2026
Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
The efficacy and safety of duloxetine in treating refractory chronic cough: a randomized clinical trial
Shengyuan Wang1, Heng Wu2, Yaxing Zhou1
1Department of Pulmonary and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Background:
Enhanced cough sensitivity is proposed as a potential cause for refractory chronic cough (RCC), and modulation of sensory nerve hyperresponsiveness is suggested as an effective treatment. However, the treatment of RCC has considerable potential for enhancement, particularly in terms of the targets and side effects. We aimed to investigate the efficacy and safety of duloxetine, a selective 5-HT and norepinephrine reuptake inhibitor, in patients with RCC.
Methods:
This is a prospective, randomized, double-blind trial. RCC patients without mood disorders in the Tongji Hospital of Tongji University outpatient clinic were invited to participate in this study. Patients were randomly assigned to the duloxetine group or placebo group, with both patients and investigators being masked. The co-primary endpoint was the change in Leicester cough questionnaire (LCQ) score and cough frequency.
Results:
Between Oct 2020 and May 2024, 98 patients were randomly assigned to duloxetine (n = 49) and placebo (n = 49) groups. After an 8-week treatment phase and a 3-week follow-up period, the mean number of coughs per hour in the duloxetine group was reduced from 83.96 ± 28.95 to 33.12 ± 22.99, showing a significant decrease than that of the placebo group (87.67 ± 31.75 to 80.36 ± 31.75) (p < 0.001). In addition, duloxetine significantly improved scores on the LCQ (12.75 ± 2.44 to 14.88 ± 2.45), whereas no significant reduction was observed in the placebo group (12.17 ± 2.64 to 12.81 ± 2.32) (P < 0.001 between groups). However, adverse events such as nausea 5 (11.36%), dizziness 7 (15.91%), and somnolence 4 (9.09%) occurred more frequently in the duloxetine group (all P < 0.05).
Conclusions:
Duloxetine reduced cough frequency and sensitivity, which appears to be a novel therapeutic approach for RCC.
Trial Registration:
The study was approved by the Ethics Committee of Shanghai Tongji Hospital (2020-KYSB-160, 2021-086) and registered in the Chinese Clinical Trial Registry (ChiCTR2000037429).
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...